Hans Beier Ommen

2.3k total citations
44 papers, 1.1k citations indexed

About

Hans Beier Ommen is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Hans Beier Ommen has authored 44 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 20 papers in Molecular Biology and 18 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Hans Beier Ommen's work include Acute Myeloid Leukemia Research (33 papers), Acute Lymphoblastic Leukemia research (18 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers). Hans Beier Ommen is often cited by papers focused on Acute Myeloid Leukemia Research (33 papers), Acute Lymphoblastic Leukemia research (18 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers). Hans Beier Ommen collaborates with scholars based in Denmark, United States and United Kingdom. Hans Beier Ommen's co-authors include Peter Hokland, Henrik Hasle, Susanne Schnittger, Jelena Jovanović, David Grimwade, Charlotte Guldborg Nyvold, Mette Østergaard, Sarah B. Daly, Josep Nomdedéu and Aline Renneville and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hans Beier Ommen

42 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hans Beier Ommen Denmark	17	940	544	430	195	163	44	1.1k
Iris H.I.M. Hollink Netherlands	19	848 0.9×	684 1.3×	313 0.7×	144 0.7×	162 1.0×	35	1.2k
S Chatters United Kingdom	6	1.3k 1.4×	521 1.0×	416 1.0×	382 2.0×	150 0.9×	8	1.4k
Jessica Kohlschmidt United States	19	765 0.8×	574 1.1×	198 0.5×	239 1.2×	313 1.9×	50	1.1k
Marta Pratcorona Spain	14	791 0.8×	572 1.1×	214 0.5×	269 1.4×	193 1.2×	29	1.0k
Tamara Weiss Germany	9	945 1.0×	462 0.8×	305 0.7×	456 2.3×	117 0.7×	22	1.1k
Joseph O. Moore United States	10	1.0k 1.1×	555 1.0×	350 0.8×	368 1.9×	100 0.6×	17	1.3k
Annika Dufour Germany	14	656 0.7×	414 0.8×	154 0.4×	253 1.3×	128 0.8×	33	843
Kristiina Heinonen Finland	16	714 0.8×	364 0.7×	369 0.9×	190 1.0×	74 0.5×	30	918
Kerstin Görlich Germany	11	690 0.7×	470 0.9×	131 0.3×	289 1.5×	173 1.1×	15	862
Mareike Rasche Germany	12	500 0.5×	328 0.6×	294 0.7×	76 0.4×	137 0.8×	27	764

Countries citing papers authored by Hans Beier Ommen

Since Specialization

Citations

This map shows the geographic impact of Hans Beier Ommen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Beier Ommen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Beier Ommen more than expected).

Fields of papers citing papers by Hans Beier Ommen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Beier Ommen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Beier Ommen. The network helps show where Hans Beier Ommen may publish in the future.

Co-authorship network of co-authors of Hans Beier Ommen

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Beier Ommen. A scholar is included among the top collaborators of Hans Beier Ommen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Beier Ommen. Hans Beier Ommen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ommen, Hans Beier, et al.. (2024). Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning. European Journal Of Haematology. 112(4). 601–610. 5 indexed citations

Othman, Jad, Nicola Potter, Adam Ivey, et al.. (2024). Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 143(19). 1931–1936. 33 indexed citations

Severinsen, Marianne Tang, et al.. (2023). Prophylaxis with low dose tranexamic acid in acute myeloid leukemia patients undergoing intensive chemotherapy. SHILAP Revista de lepidopterología. 4(3). 690–694. 2 indexed citations

Grove, Erik Lerkevang, et al.. (2022). Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia. British Journal of Haematology. 198(4). 693–702. 4 indexed citations

Dillon, Richard, Aimee Jackson, Sonia Fox, et al.. (2022). Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. BMC Cancer. 22(1). 1174–1174. 2 indexed citations

Hvas, Anne‐Mette, et al.. (2021). Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease. SHILAP Revista de lepidopterología. 5(3). e230–e238. 3 indexed citations

Lausen, Birgitte, Linda Holmfeldt, Anni Aggerholm, et al.. (2021). Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia. Journal of Molecular Diagnostics. 23(12). 1787–1799. 3 indexed citations

Ommen, Hans Beier, et al.. (2021). Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse. British Journal of Haematology. 195(3). 310–327. 11 indexed citations

Jakobsen, Lasse Hjort, Anne Stidsholt Roug, Claus Werenberg Marcher, et al.. (2020). Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000–2016: a Danish population‐based study. British Journal of Haematology. 193(3). 482–487. 17 indexed citations

10.

Ommen, Hans Beier, Charlotte Guldborg Nyvold, Christiane Walter, et al.. (2020). Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia. British Journal of Haematology. 190(2). 198–208. 19 indexed citations

11.

Hønge, Bo Langhoff, et al.. (2020). Successful use of extracorporeal membrane oxygenation in respiratory failure due to influenza and acute myeloid leukemia. International Journal of Infectious Diseases. 96. 570–572.

12.

Hansen, Marcus Høy, et al.. (2017). Case report: Exome sequencing identifies T-ALL with myeloid features as a IKZF1-struck early precursor T-cell malignancy. Leukemia Research Reports. 9. 1–4. 7 indexed citations

13.

Ommen, Hans Beier. (2015). Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies. Therapeutic Advances in Hematology. 7(1). 3–16. 57 indexed citations

14.

Hansen, Marcus Høy, Judit Jørgensen, Anni Aggerholm, et al.. (2014). Delineation of known and new transcript variants of the SETMAR (Metnase) gene and the expression profile in hematologic neoplasms. Experimental Hematology. 42(6). 448–456.e4. 14 indexed citations

15.

Ommen, Hans Beier, et al.. (2013). A novel RT‐qPCR assay for quantification of the MLL‐MLLT3 fusion transcript in acute myeloid leukaemia. European Journal Of Haematology. 91(5). 394–398. 6 indexed citations

16.

Hokland, Peter, Hans Beier Ommen, Charlotte Guldborg Nyvold, & Anne Stidsholt Roug. (2012). Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission – methodologies in relation to their clinical situation. British Journal of Haematology. 158(5). 569–580. 23 indexed citations

17.

Aggerholm, Anni, et al.. (2009). The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML. European Journal Of Haematology. 83(5). 439–448. 28 indexed citations

18.

Lo, Miao‐Chia, Luke F. Peterson, Ming Yan, et al.. (2008). Identification of the JAK/STAT Signaling Pathway as a Valid Therapeutic Target of T(8;21) Acute Myeloid Leukemia Using Combined Gene Expression and Promoter Occupancy Profiling.. Blood. 112(11). 3336–3336. 1 indexed citations

19.

Nyvold, Charlotte Guldborg, Hans Beier Ommen, Mette Østergaard, & Peter Hokland. (2007). Reply to ‘Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML’ by Summers et al.. Leukemia. 21(3). 552–552. 1 indexed citations

20.

Plašilová, Magdalena, Hans Beier Ommen, Jaroslav Jelı́nek, et al.. (2006). Loss of Heterozygosity (LOH) of the NUP98 Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML).. Blood. 108(11). 2356–2356. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact